"Immune efficacy can be maintained for over at least 8 months"
[Asia Economy Reporter Kim Suhwan] The U.S. pharmaceutical company Johnson & Johnson (J&J) announced that its Janssen COVID-19 vaccine demonstrates strong immune efficacy against the Delta variant and can maintain immune protection for over eight months after completing vaccination.
On the 1st (local time), J&J released a statement confirming that its Janssen vaccine has powerful immune efficacy capable of neutralizing the Delta variant. The company also added that this effect is observed with the existing vaccine doses alone, without the need for an additional booster shot to enhance immunity.
This announcement is based on interim results from clinical trials conducted by J&J on the Delta variant. The company stated that they confirmed this immune efficacy through blood samples from the trial participants.
J&J further mentioned that the final results of the Delta variant clinical trial will soon be published on the medical research platform bioRxiv.
A J&J representative said, "We are very pleased that the vaccine can provide immune efficacy against various variants without the need for a booster shot."
Unlike other vaccines that typically require two doses, the Janssen vaccine is administered as a single dose. According to J&J, one dose of the Janssen vaccine can neutralize the Delta variant within up to 29 days.
The company also stated that immune efficacy is maintained for at least eight months following vaccination with the Janssen vaccine.
J&J indicated that individuals who have already received the Janssen vaccine are unlikely to need a booster shot for up to one year after vaccination.
Moreover, even if additional variants emerge that require booster shots, J&J expects that minor adjustments to the existing vaccine will be sufficient to provide adequate immune protection.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
